These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 14534526)

  • 1. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
    Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
    Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
    N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
    Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
    Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.
    Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M
    Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
    Boulet AP; Tessier G
    Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
    Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
    CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of the prescribing of potentially inappropriate medications at ambulatory care visits by elderly patients covered by the Taiwanese National Health Insurance program.
    Lai HY; Hwang SJ; Chen YC; Chen TJ; Lin MH; Chen LK
    Clin Ther; 2009 Aug; 31(8):1859-70. PubMed ID: 19808145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
    Li X; Guh D; Lacaille D; Esdaile J; Anis AH
    Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia.
    Grootendorst P; Stewart D
    Health Econ; 2006 Jul; 15(7):735-42. PubMed ID: 16498702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The estimated costs and savings of medical nutrition therapy: the Medicare population.
    Sheils JF; Rubin R; Stapleton DC
    J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.
    Duetz MS; Schneeweiss S; Maclure M; Abel T; Glynn RJ; Soumerai SB
    Clin Ther; 2003 Jan; 25(1):273-84. PubMed ID: 12637126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma.
    Dormuth CR; Glynn RJ; Neumann P; Maclure M; Brookhart AM; Schneeweiss S
    Clin Ther; 2006 Jun; 28(6):964-78; discussion 962-3. PubMed ID: 16860179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.
    Bourgault C; Elstein E; Le Lorier J; Suissa S
    CMAJ; 1999 Aug; 161(3):255-60. PubMed ID: 10463046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
    Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
    CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.
    Schneeweiss S; Patrick AR; Maclure M; Dormuth CR; Glynn RJ
    Circulation; 2007 Apr; 115(16):2128-35. PubMed ID: 17420348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
    Hanley GE; Morgan S
    Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging.
    Maxwell CJ; Hogan DB; Ebly EM
    CMAJ; 1999 Sep; 161(5):501-6. PubMed ID: 10497605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000.
    Pilote L; Beck CA; Karp I; Alter D; Austin P; Cox J; Humphries K; Jackevicius C; Richard H; Tu JV;
    Can J Cardiol; 2004 Jan; 20(1):61-7. PubMed ID: 14968144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating reference-based pricing: initial findings and prospects.
    Narine L; Senathirajah M; Smith T
    CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.